What patients actually need to know before choosing a clinic, and the questions most providers hope you won’t ask.
If you’ve spent any time researching stem cell therapy, you’ve probably noticed something strange: every clinic sounds like it’s offering the same thing. They’re not.
“Stem cells” is not a single product. It’s a category so broad that two clinics can both use the phrase, in good faith, and be describing biologics that are fundamentally different in their source, manufacturing, potency, and appropriate use.
A patient comparing options without understanding this distinction isn’t comparing treatments. They’re comparing marketing. That’s worth unpacking.
The six (very different) things clinics call “stem cells”
| Type | Description |
|---|---|
| Platelet-Rich Plasma (PRP/PRGF) | PRP is drawn from your own blood, spun to concentrate platelets, and injected back into a target area. It releases growth factors that support tissue healing. It’s a legitimate tool in orthopedics and aesthetics, but it contains no stem cells. Calling it a stem cell therapy is technically inaccurate, though it’s common. |
| Bone Marrow Aspirate Concentrate (BMAC) | BMAC is collected from the patient’s own hip bone and processed same-day. It does contain some mesenchymal stem cells, but the number varies significantly depending on the patient’s age, metabolic health, and inflammatory status. A 60-year-old with chronic inflammation may produce a fraction of the cells a healthier 40-year-old would. You can’t control the dose. |
| Adipose-Derived Stromal Vascular Fraction (SVF) | SVF is extracted from fat tissue, usually via liposuction, and contains a mixed population of cells — some with regenerative properties, others without. Regulatory status varies by country, and the product is not comparable to expanded, characterized mesenchymal stem cells. The variability is the issue: what you get depends on how the procedure is performed and what the lab does with the tissue. |
| Cord Blood | Cord blood is rich in hematopoietic stem cells, which are the progenitors of blood and immune cells. These have well-established uses in bone marrow reconstitution after cancer treatment. They are not the same as mesenchymal stem cells, and cord blood products are not appropriate for most of the regenerative protocols patients research online. |
| Amniotic, Placental, and “Wharton’s Jelly Tissue” Products | This category is where patient skepticism is most warranted. These terms are often used interchangeably in marketing, but they can describe anything from acellular tissue products, which contain no live cells at all, to products that do contain viable cells with proper documentation. The phrase “Wharton’s Jelly” alone tells you nothing about quality. Before accepting any claim in this category, a patient should ask for documentation: viable cell counts, identity markers, sterility results, and chain of custody. |
| Expanded Wharton’s Jelly UC-MSCs | This is a different category. Umbilical cord mesenchymal stem cells, or UC-MSCs, are isolated from Wharton’s Jelly — the connective tissue inside the umbilical cord — and then expanded under controlled laboratory conditions. When manufactured properly, these cells allow something the other categories mostly don’t: defined dosing, confirmed identity, viability testing, and complete batch records. The cells are young, from full-term donated cords, not patients, allogeneic, donor-derived, not autologous, and can be tested before release. |
| UC-MSC-Derived Exosomes | Exosomes are not cells. They’re extracellular vesicles, tiny packages secreted by cells that carry proteins, growth factors, and signaling molecules. When produced by UC-MSC cultures, they carry much of the regenerative communication capacity of the parent cells without the logistics of live cell administration. Their quality depends entirely on the quality of the parent cells, the purification process, and whether they’ve been tested for particle size, concentration, sterility, endotoxin, and mycoplasma. Exosomes produced by a high-quality UC-MSC lab are a meaningful biologic. Exosomes produced by an uncharacterized cell source are not. |
Why the U.S. market creates so much confusion
The United States has FDA-approved cell and gene therapies. It also has a large gray area where clinics offer procedures under various regulatory interpretations.
What patients often don’t realize is that FDA approval is product-specific. An approval for one defined product, in one manufacturing process, for one indication doesn’t license every clinic to offer any biologic for any purpose. In routine U.S. clinical practice, patients can typically access PRP, BMAC, and FDA-approved therapies for specific labeled conditions.
Expanded allogeneic Wharton’s Jelly UC-MSCs for systemic regenerative protocols, the type of treatment patients frequently research, are not available in this way in the U.S. under current FDA guidance. That’s not a condemnation of the therapy; it reflects where U.S. regulatory processes currently stand with expanded allogeneic cells.
A patient comparing a U.S. bone marrow aspirate procedure to an expanded UC-MSC protocol at a licensed international clinic isn’t comparing two versions of the same treatment. They’re comparing different biologics entirely.
What “pharmaceutical grade” actually means, and what it doesn’t
Words like “premium,” “pharmaceutical grade,” “high dose,” and “advanced formula” are not regulated terms in most markets. Any clinic can use them. What matters is whether those claims are supported by documentation.
A biologic with serious quality controls should be backed by records in each of these areas:
| Chain of custody | A traceable path from donor tissue to processing, expansion, cryostorage, final vial, release, and patient administration. If a vial can't be traced back to a donor and a set of test results, that's a gap. |
| Identity confirmation | Flow cytometry data confirming MSC surface markers: CD73, CD90, and CD105 positive; CD34, CD45, and HLA-DR negative. These are the markers that distinguish genuine MSCs from other cell types. |
| Viability measurement | A confirmed live-cell percentage at release and/or post-thaw, against a defined threshold. If the clinic doesn't test viability, they don't know what's in the vial. |
| Sterility and contamination testing | Sterility culture, mycoplasma testing, endotoxin testing. These are non-negotiable for any injectable biologic. |
| Exosome characterization | For exosome products: particle size and concentration, typically via nanoparticle tracking analysis, protein content, sterility, endotoxin, and mycoplasma. Without these, the "exosome" product is uncharacterized. |
| Medical integration | Physician review of the patient's indication, contraindications, appropriate route and dose, supportive therapies, and follow-up plan. A vial doesn't read medical history. |
A quality biologic is not a complete treatment
Even when the product is excellent, a vial doesn’t constitute a protocol.
Route of administration matters. Intravenous delivery has different reach and duration than a joint injection or a localized scalp delivery. Dose matters, more isn’t always appropriate; it depends on the patient’s inflammatory load, metabolic status, and clinical presentation. Preparation matters: certain pre-treatment protocols can improve cellular uptake and reduce the inflammatory environment that would otherwise blunt the response.
OmniStem approaches regenerative care as a system: medical evaluation, in-house biologic production with full quality testing, clinical administration, integrated supportive therapies (HBOT, ozone, nutrition), and documented follow-up. Each element affects the outcome of the others. A high-quality biologic administered without appropriate medical oversight is still incomplete care.
The questions a serious clinic should be able to answer
Before committing to any regenerative program, a patient should get plain answers, not brochure language, to each of these:
| Are you licensed for cellular therapy services in your jurisdiction? |
| Who manufactures the biologics, and where? |
| Are the cells expanded in your own laboratory, or purchased from a third party? |
| What source tissue is used, and how is donor eligibility confirmed? |
| What MSC identity markers are tested, and what are the release criteria? |
| What is the viability at release and post-thaw? |
| Are sterility, mycoplasma, and endotoxin tested on every batch? |
| For exosomes: what is the parent cell source, and how are particles characterized? |
| Can donor tissue be traced to the final vial and patient record? |
| Who determines route, dose, and contraindications, and what is the follow-up protocol? |
If the answers are vague, or if the clinic redirects to testimonials and outcome claims rather than documentation, that is meaningful information.
The bottom line
Regenerative medicine will not be defined by who uses the phrase “stem cells.” It will be defined by which clinics actually produce and administer biologics that are tested, traceable, and administered within a real medical framework.
OmniStem operates a vertically integrated clinic-laboratory in Punta Cana, producing UC-MSCs and exosomes in-house under Ministry of Health oversight. Every biologic is triple-certified for sterility, viability, and identity before release. Every protocol is physician-led, medically evaluated, and documented.
For patients who have done enough research to know the difference, that distinction matters.
Begin with a medical review
OmniStem provides physician-led regenerative consultations for patients considering UC-MSC and exosome-based protocols. Every protocol requires medical evaluation. Outcomes vary and no result is guaranteed.
Educational material only. This article does not replace individualized medical advice, diagnosis, informed consent, or treatment by a qualified physician. Regenerative therapies require medical evaluation. Outcomes vary by patient, condition, and protocol. OmniStem does not diagnose, treat, cure, or guarantee reversal of any disease or symptom.
